BPC-157 + TB-500 blend

What it is

This is a pre-mixed vial of two peptides: BPC-157 (a stomach-derived 15-amino-acid peptide linked to tendon, gut and soft-tissue healing in animal studies) and TB-500 (a synthetic fragment related to thymosin beta-4, linked to cell migration and repair). The combination is nicknamed the 'Wolverine' stack, after the comic-book character with the fast healing, which tells you more about the marketing than the evidence.

We stock two sizes, both at a 1:1 ratio: 10 mg (5 mg BPC-157 + 5 mg TB-500) and 20 mg (10 mg + 10 mg). The appeal is one vial and one injection. The catch is that nobody has studied the combination in people, and both individual peptides have almost no controlled human data.

History

The stack has no research history of its own. It became popular in athlete and biohacker communities in the 2010s and 2020s as the default 'injury recovery' pairing. BPC-157 was first described in the early 1990s by researchers in Zagreb. TB-500 comes from thymosin beta-4, studied since the 1980s, and has a long grey-market history in equestrian sport.

How it works

There is no mechanism data for the combination, only for the parts. BPC-157 is thought to promote new blood vessel formation and repair signalling at injury sites. TB-500 is thought to act on actin, helping cells migrate to damaged areas. The theory is that they act on different parts of repair so might complement each other. That is a theory, not a result.

Dosage

• There is no established human dose. Community ranges are extrapolated from animal work and anecdote.
• A commonly reported approach is about 250-500 mcg each of BPC-157 and TB-500 per injection, once daily or every other day, for 4-6 weeks, then a break.
• Many people use TB-500 at higher, less frequent doses on its own (for example 2-2.5 mg twice weekly). With a 1:1 blend you cannot do that without taking far more BPC-157 than usual. This is the main practical limit of the blend.
• Because the ratio is fixed, separate vials are the only way to adjust one component independently.

How it is taken

• Subcutaneous injection into belly fat with a 29-31G insulin syringe is the most common route.
• Some users inject subcutaneously or intramuscularly close to the injured area. The evidence that site-specific injection beats injecting elsewhere in humans is weak.
• Rotate injection sites to reduce irritation and lumps.

How to reconstitute

• 10 mg vial (5 mg BPC-157 + 5 mg TB-500): add 2 ml bacteriostatic water. That is 5 mg/ml total, or 2.5 mg/ml of each. On a 1 ml / 100-unit syringe, 10 units (0.1 ml) = 0.25 mg of each peptide (0.5 mg of blend). 20 units = 0.5 mg of each.
• 20 mg vial (10 mg BPC-157 + 10 mg TB-500): add 2 ml bacteriostatic water. That is 10 mg/ml total, or 5 mg/ml of each. 5 units (0.05 ml) = 0.25 mg of each (0.5 mg of blend). 10 units = 0.5 mg of each.
• Check your vial's label first. Always work from the amounts printed on your own vial.
• Add the water slowly down the inside wall of the vial. Swirl gently. Do not shake.

How it should arrive

Sealed glass vial with an intact crimped cap and a white to off-white powder cake at the bottom. Neither peptide is coloured, so unlike GHK-Cu blends the powder should be white.

How it should look once reconstituted

A clear, colourless solution with no cloudiness, flecks or residue. Cloudy or stringy solution means do not use it.

What to expect, and when

• Anecdotally, people report changes in pain or movement from about 1-3 weeks, with a typical course of 4-6 weeks.
• Tendon and ligament problems heal slowly regardless; do not expect quick fixes.
• If you notice nothing after 4-6 weeks of consistent use, the realistic conclusion is that it is not doing anything for you.

Side effects

• Most reports describe it as well tolerated, but that is self-reported.
• Injection-site redness, itching, soreness or small lumps.
• Occasional headache, tiredness, light-headedness or nausea, reported for both components.
• With a blend, you cannot tell which ingredient caused a reaction without stopping and testing them separately.

Risks

• No human safety data exists for the combination, and each component has almost no controlled human data.
• Both peptides are thought to promote blood vessel growth and tissue repair. That is why they are interesting, and also why long-term safety, including tumour risk, has not been ruled out. If you have a cancer history or a suspected tumour, this is a good reason to avoid them.
• Quality varies. Blends are harder to verify than single peptides, and a seller can under-dose one component and the vial still looks fine. Third-party testing is the only real check.
• Masking an injury is a real risk: feeling better does not mean the tissue is fully healed, and loading too early can cause re-injury.
• Both are banned for competitive athletes under WADA rules. Neither is a licensed medicine for human use anywhere.

Potential gains

• Convenience: one vial and one injection in place of two.
• Reported faster recovery from tendon, ligament, muscle and joint injuries. The evidence is animal studies and anecdote.
• No trial shows the combination works better than either peptide alone.

Other useful information

Which vial to choose: the 20 mg vial lasts twice as long, but reconstituted vials are only good for about 3-4 weeks, so do not buy more than you will use in that time. At 0.25-0.5 mg of each per dose, the 10 mg vial gives roughly 10-20 injections. For a specific injury, buying BPC-157 and TB-500 separately gives you control over each dose, which is usually worth the extra vial.